2162 — Keymed Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- HK$21.31bn
- HK$20.02bn
- CNY716.31m
Annual cashflow statement for Keymed Biosciences, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -3,893 | -304 | -356 | -509 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 3,654 | -129 | -37.7 | -47.4 | — |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.83 | -5.67 | 21.1 | -327 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -215 | -402 | -304 | -790 | — |
| Capital Expenditures | -173 | -280 | -383 | -214 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -1,863 | -366 | 851 | 282 | — |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2,036 | -646 | 468 | 67.7 | — |
| Financing Cash Flow Items | -53.5 | -32.4 | -164 | -16.9 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3,638 | -8.06 | 72.1 | 284 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1,321 | -917 | 247 | -433 | — |